Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.31 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19746826 | 1.00 | FAAH (0.35) | FAAHCA12CA14MEN1KMT2A | |
| SCHEMBL15663456 | 0.80 | FAAH (0.37) | FAAHMEN1KMT2ACTSLCTSB | |
| SCHEMBL17131832 | 0.80 | FAAH (0.37) | FAAHCA12CA14MEN1KMT2A | |
| SCHEMBL3154599 | 0.80 | FAAH (0.37) | FAAHMEN1KMT2ACTSLCTSB | |
| SCHEMBL288906 | 0.80 | FAAH (0.37) | FAAHMEN1KMT2ACTSLCTSB | |
| SCHEMBL8383198 | 0.80 | JAK3 (0.32) | FAAH | |
| SCHEMBL2969312 | 0.79 | MMP9 (0.35) | MEN1KMT2ACTSLCTSBCTSS | |
| SCHEMBL15228983 | 0.79 | MMP9 (0.35) | MEN1KMT2ACTSLCTSBCTSS | |
| SCHEMBL8647682 | 0.79 | JAK3 (0.32) | — | |
| Ammonia Solution, Strong SCHEMBL15303247 | 0.78 | FAAH (0.36) | FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117529476-A | Preparation of substituted 1, 2-diamino heterocyclic derivatives and their use as medicaments | 亚飞络思制药公司 | 2024-02-06 | — | — | CN | disclosed |
| US-20230192659-A1 | N-(HETEROCYCLYL AND HETEROCYCLYLALKYL)-3-BENZYLPYRIDIN-2-AMINE DERIVATIVES AS SSTR4 AGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-06-22 | — | — | US | disclosed |
| EP-4126849-A1 | N-(HETEROCYCLYL AND HETEROCYCLYLALKYL)-3-BENZYLPYRIDIN-2-AMINE DERIVATIVES AS SSTR4 AGONISTS | Takeda Pharmaceutical Company Limited (JP) | 2023-02-08 | — | — | EP | disclosed |
| EP-3472130-B1 | ALIPHATIC PROLINAMIDE DERIVATIVES | Orion Ophthalmology LLC (US) | 2022-02-16 | — | — | EP | disclosed |
| WO-2021202775-A1 | N-(HETEROCYCLYL AND HETEROCYCLYLALKYL)-3-BENZYLPYRIDIN-2-AMINE DERIVATIVES AS SSTR4 AGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-10-07 | — | — | WO | disclosed |
| EP-3484859-B1 | NEW DIFLUOROKETAMIDE DERIVATIVES AS HTRA1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2021-09-15 | — | — | EP | disclosed |
| US-11059858-B2 | Difluoroketamide derivatives as HtrA1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2021-07-13 | — | — | US | disclosed |
| US-11001555-B2 | Difluoroketamide derivatives as HTRA1 inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2021-05-11 | — | — | US | disclosed |
| US-10995084-B2 | Pyrrolidine derivative | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2021-05-04 | — | — | US | disclosed |
| EP-3423467-B1 | NEW DIFLUOROKETAMIDE DERIVATIVES AS HTRA1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2021-04-28 | — | — | EP | disclosed |
| US-20190152895-A1 | NEW DIFLUOROKETAMIDE DERIVATIVES AS HTRAl INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2019-05-23 | — | — | US | disclosed |
| EP-3472130-A1 | ALIPHATIC PROLINAMIDE DERIVATIVES | ORION OPTHALMOLOGY LLC (US) | 2019-04-24 | — | — | EP | disclosed |
| EP-3459941-A1 | PYRROLIDINE DERIVATIVE | Kissei Pharmaceutical Co., Ltd. (JP) | 2019-03-27 | — | — | EP | disclosed |
| US-20180371015-A1 | NEW DIFLUOROKETAMIDE DERIVATIVES AS HTRA1 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2018-12-27 | — | — | US | disclosed |
| WO-2018036942-A1 | NEW DIFLUOROKETAMIDE DERIVATIVES AS HTRA1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2018-03-01 | — | — | WO | disclosed |
| WO-2017222917-A1 | ALIPHATIC PROLINAMIDE DERIVATIVES | INCEPTION 4, INC. (US) | 2017-12-28 | — | — | WO | disclosed |
| US-7498353-B2 | Heterocyclic anti-viral compounds comprising metabolizable moieties and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2009-03-03 | — | — | US | disclosed |
| EP-1883633-A2 | HETEROCYCLIC ANTI-VIRAL COMPOUNDS COMPRISING METABOLIZABLE MOIETIES AND THEIR USES | Rigel Pharmaceuticals, Inc. (US) | 2008-02-06 | — | — | EP | disclosed |
| WO-2007027230-A2 | HETEROCYCLIC ANTI-VIRAL COMPOUNDS COMPRISING METABOLIZABLE MOIETIES AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2007-03-08 | — | — | WO | disclosed |
| US-20060247287-A1 | Heterocyclic Anti-Viral Compounds Comprising Metabolizable Moieties And Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10995084-B2 | Pyrrolidine derivative | CALCRL, NPY1R, GRPR | FAAH 905/4885CA12 4420/4885CA14 3893/4885 |
| US-11001555-B2 | Difluoroketamide derivatives as HTRA1 inhibitors | HTRA1, HTR1A, HTR1F | FAAH 383/4885CA12 4854/4885CA14 4792/4885 |
| US-11059858-B2 | Difluoroketamide derivatives as HtrA1 inhibitors | HTRA1, HTR1A, HTR1E | FAAH 507/4885CA12 4856/4885CA14 4833/4885 |
| US-20060247287-A1 | Heterocyclic Anti-Viral Compounds Comprising Metabolizable Moieties And Their Uses | HAVCR2, HCCS, AADAC | FAAH 961/4885CA12 3277/4885CA14 2826/4885 |
| US-20180371015-A1 | NEW DIFLUOROKETAMIDE DERIVATIVES AS HTRA1 INHIBITORS | HTRA1, HTR1A, HTR1E | FAAH 405/4885CA12 4873/4885CA14 4839/4885 |
| US-20190152895-A1 | NEW DIFLUOROKETAMIDE DERIVATIVES AS HTRAl INHIBITORS | HTRA1, HTR6, HTR1E | FAAH 632/4885CA12 4870/4885CA14 4820/4885 |
| US-20230192659-A1 | N-(HETEROCYCLYL AND HETEROCYCLYLALKYL)-3-BENZYLPYRIDIN-2-AMINE DERIVATIVES AS SSTR4 AGONISTS | SSTR4, SSTR3, SSTR1 | FAAH 1461/4885CA12 2647/4885CA14 1863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.